Overall survival. At 36 months the actuarial proportion of patients alive was 91% (95% CI, 87%-94%) in the high-dose arm (HDA) and 84% (95% CI, 78%-90%) in the standard-dose arm (SDA). P = .79, log-rank test. No patient was censored before last contact or death. Total number of deaths was 7 in the HDA and 8 in the SDA.